sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agentes antineoplásicos - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
bonar
achÉ laboratÓrios farmacÊuticos s.a - sulfato de bleomicina - antibioticos antineoplasicos
evoflubina
farmarin industria e comercio ltda - fosfato de fludarabina - antineoplasico
fludalibbs
libbs farmacÊutica ltda - fosfato de fludarabina - antimetabolicos analogos da purina
nexavar
bayer s.a. - tosilato de sorafenibe - antineoplasico
vivaxxia
libbs farmacÊutica ltda - rituximabe - antineoplasico
evoflubina
evolabis produtos farmacÊuticos ltda - antineoplasico
evoflubina
hospira produtos hospitalares ltda - antineoplasico
evoflubina
wyeth indÚstria farmacÊutica ltda - antineoplasico
ruxience
pfizer brasil ltda - rituximabe - antineoplasicos citotoxicos